Login / Signup

Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain.

Juan Antonio Trigueros CarreroNoé GarinAdolfo BaloiraSusana AceitunoAna CalvoMiriam PradesCarolina TouronAnisia MartínezCovadonga Torres
Published in: International journal of chronic obstructive pulmonary disease (2022)
BUD/GLY/FOR is a cost-effective treatment strategy for Spanish NHS patients with COPD compared to dual therapies.
Keyphrases
  • chronic obstructive pulmonary disease
  • patient safety
  • lung function
  • stem cells
  • mesenchymal stem cells
  • combination therapy